2020 PDC Summit Webinar Series: Car-T Therapy's Impact on the Patient Pathway

While we are all aware of the potential that precision medicine promises, can we effectively design facilities to accommodate these novel therapies? This session will present HDR's research on this topic. We will review how the question our City of Hope client asked about Car-T cell therapy impact on inpatient volume turned into a six-month-long research study. During this session you will be provided with case studies from prominent cancer institutions on their facility responses. Also, HDR will demonstrate our analytical tools that quantify the impact that Cytokine Release Syndrome has on immunotherapy readmission and how this impacts the metrics for inpatient bed need.

Learning Objectives:

• Produce an informed response to a difficult programming question
• Evaluate built facilities' responses to novel therapies
• Assess how parametric modeling can assist in analyzing inpatient metrics
• View how future patient pathways impact facility design

Speaker(s):

• Michael Roughan, AIA, ACHA, Vice President, Health Principal, HDR
• Kathleen Woods, MSN RN EDAC, Senior Healthcare Consultant, HDR
• Sherman Moore, VP, Strategy, City of Hope Cancer Center
• Garth Highland, Data Scientist, HDR